Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,836
archived clinical trials in
Leukemia

Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia
Status: Enrolling
Updated:  11/23/2015
Presbyterian Cancer Center at Presbyterian Hospital
mi
from
Charlotte, NC
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia
Status: Enrolling
Updated: 11/23/2015
Presbyterian Cancer Center at Presbyterian Hospital
mi
from
Charlotte, NC
Click here to add this to my saved trials
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia
Status: Enrolling
Updated:  11/23/2015
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia
Status: Enrolling
Updated: 11/23/2015
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia
Status: Enrolling
Updated:  11/23/2015
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia
Status: Enrolling
Updated: 11/23/2015
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia
Status: Enrolling
Updated:  11/23/2015
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia
Status: Enrolling
Updated: 11/23/2015
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia
Status: Enrolling
Updated:  11/23/2015
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia
Status: Enrolling
Updated: 11/23/2015
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia
Status: Enrolling
Updated:  11/23/2015
Rhode Island Hospital Comprehensive Cancer Center
mi
from
Providence, RI
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia
Status: Enrolling
Updated: 11/23/2015
Rhode Island Hospital Comprehensive Cancer Center
mi
from
Providence, RI
Click here to add this to my saved trials
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia
Status: Enrolling
Updated:  11/23/2015
Miriam Hospital
mi
from
Providence, RI
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia
Status: Enrolling
Updated: 11/23/2015
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia
Status: Enrolling
Updated:  11/23/2015
Mountainview Medical
mi
from
Berlin, VT
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia
Status: Enrolling
Updated: 11/23/2015
Mountainview Medical
mi
from
Berlin, VT
Click here to add this to my saved trials
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia
Status: Enrolling
Updated:  11/23/2015
Fletcher Allen Health Care - University Health Center Campus
mi
from
Burlington, VT
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia
Status: Enrolling
Updated: 11/23/2015
Fletcher Allen Health Care - University Health Center Campus
mi
from
Burlington, VT
Click here to add this to my saved trials
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia
Status: Enrolling
Updated:  11/23/2015
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia
Status: Enrolling
Updated: 11/23/2015
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Tunnell Cancer Center at Beebe Medical Center
mi
from
Lewes, DE
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Tunnell Cancer Center at Beebe Medical Center
mi
from
Lewes, DE
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Ella Milbank Foshay Cancer Center at Jupiter Medical Center
mi
from
Jupiter, FL
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Ella Milbank Foshay Cancer Center at Jupiter Medical Center
mi
from
Jupiter, FL
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Mount Sinai Medical Center CCOP
mi
from
Miami Beach, FL
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Mount Sinai Medical Center CCOP
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Graham Hospital
mi
from
Canton, IL
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Graham Hospital
mi
from
Canton, IL
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Memorial Hospital
mi
from
Carthage, IL
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Memorial Hospital
mi
from
Carthage, IL
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Eureka Community Hospital
mi
from
Eureka, IL
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Eureka Community Hospital
mi
from
Eureka, IL
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Evanston Northwestern Healthcare - Evanston Hospital
mi
from
Evanston, IL
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Evanston Northwestern Healthcare - Evanston Hospital
mi
from
Evanston, IL
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Galesburg Clinic, PC
mi
from
Galesburg, IL
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Galesburg Clinic, PC
mi
from
Galesburg, IL
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Galesburg Cottage Hospital
mi
from
Galesburg, IL
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Galesburg Cottage Hospital
mi
from
Galesburg, IL
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Mason District Hospital
mi
from
Havana, IL
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Mason District Hospital
mi
from
Havana, IL
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Hopedale Medical Complex
mi
from
Hopedale, IL
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Hopedale Medical Complex
mi
from
Hopedale, IL
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
McDonough District Hospital
mi
from
Macomb, IL
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
McDonough District Hospital
mi
from
Macomb, IL
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
BroMenn Regional Medical Center
mi
from
Normal, IL
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
BroMenn Regional Medical Center
mi
from
Normal, IL
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Community Cancer Center
mi
from
Normal, IL
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Community Cancer Center
mi
from
Normal, IL
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
OSF Saint Elizabeth Medical Center
mi
from
Ottawa, IL
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
OSF Saint Elizabeth Medical Center
mi
from
Ottawa, IL
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Oncology Hematology Associates of Central Illinois, PC - Ottawa
mi
from
Ottawa, IL
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Oncology Hematology Associates of Central Illinois, PC - Ottawa
mi
from
Ottawa, IL
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Cancer Treatment Center at Pekin Hospital
mi
from
Pekin, IL
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Cancer Treatment Center at Pekin Hospital
mi
from
Pekin, IL
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Proctor Hospital
mi
from
Peoria, IL
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Proctor Hospital
mi
from
Peoria, IL
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Oncology Hematology Associates of Central Illinois, PC - Peoria
mi
from
Peoria, IL
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Oncology Hematology Associates of Central Illinois, PC - Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Methodist Medical Center of Illinois
mi
from
Peoria, IL
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Methodist Medical Center of Illinois
mi
from
Peoria, IL
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Illinois Valley Community Hospital
mi
from
Peru, IL
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Illinois Valley Community Hospital
mi
from
Peru, IL
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Perry Memorial Hospital
mi
from
Princeton, IL
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Perry Memorial Hospital
mi
from
Princeton, IL
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Center for Cancer Care at OSF Saint Anthony Medical Center
mi
from
Rockford, IL
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Center for Cancer Care at OSF Saint Anthony Medical Center
mi
from
Rockford, IL
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
St. Margaret's Hospital
mi
from
Spring Valley, IL
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
St. Margaret's Hospital
mi
from
Spring Valley, IL
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Elkhart General Hospital
mi
from
Elkhart, IN
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Elkhart General Hospital
mi
from
Elkhart, IN
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Fort Wayne Medical Oncology and Hematology
mi
from
Fort Wayne, IN
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Fort Wayne Medical Oncology and Hematology
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
CCOP - Northern Indiana CR Consortium
mi
from
South Bend, IN
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
CCOP - Northern Indiana CR Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Memorial Hospital of South Bend
mi
from
South Bend, IN
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Memorial Hospital of South Bend
mi
from
South Bend, IN
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Central Maine Comprehensive Cancer Center at Central Maine Medical Center
mi
from
Lewiston, ME
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Central Maine Comprehensive Cancer Center at Central Maine Medical Center
mi
from
Lewiston, ME
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Union Hospital Cancer Program at Union Hospital
mi
from
Elkton MD, MD
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Union Hospital Cancer Program at Union Hospital
mi
from
Elkton MD, MD
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Lakeland Regional Cancer Care Center - St. Joseph
mi
from
St. Joseph, MI
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Lakeland Regional Cancer Care Center - St. Joseph
mi
from
St. Joseph, MI
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Veterans Affairs Medical Center - Minneapolis
mi
from
Minneapolis, MN
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Veterans Affairs Medical Center - Minneapolis
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Ellis Fischel Cancer Center at University of Missouri - Columbia
mi
from
Columbia, MO
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Ellis Fischel Cancer Center at University of Missouri - Columbia
mi
from
Columbia, MO
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
CCOP - Kansas City
mi
from
Kansas City, MO
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
CCOP - Kansas City
mi
from
Kansas City, MO
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
mi
from
Saint Louis, MO
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
Callahan Cancer Center at Great Plains Regional Medical Center
mi
from
North Platte, NE
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
Callahan Cancer Center at Great Plains Regional Medical Center
mi
from
North Platte, NE
Click here to add this to my saved trials
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  11/23/2015
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 11/23/2015
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Click here to add this to my saved trials